What is the recommended intensive phase regimen for tuberculosis treatment, including drug selection, dosing, duration, and adjustments for drug resistance?

Intensive Phase of TB Treatment

Drug-Susceptible TB

For drug-susceptible pulmonary tuberculosis, the intensive phase consists of 2 months of daily isoniazid, rifampin, pyrazinamide, and ethambutol (or streptomycin in young children), followed by a 4-month continuation phase of isoniazid and rifampin. 1

Standard Regimen Components

The preferred intensive phase regimen includes:

• Isoniazid (INH): Daily for 56 doses (8 weeks) or 5 days/week for 40 doses 1
• Rifampin (RIF): Same dosing schedule as isoniazid 1
• Pyrazinamide (PZA): Same dosing schedule as isoniazid 1
• Ethambutol (EMB): Same dosing schedule, included until drug susceptibility results confirm no resistance 1

Duration and Monitoring

• Intensive phase duration: 2 months (8 weeks) 1, 2
• Total treatment duration: 6 months for most cases 1, 2
• Extended therapy consideration: Patients with cavitation on initial chest radiograph AND positive cultures at 2 months should receive a 7-month continuation phase (total 9 months) 1

Key Clinical Considerations

Ethambutol can be omitted from the initial regimen only when there is <4% primary isoniazid resistance in the community, the patient has no previous TB treatment, is not from a high-prevalence drug-resistance country, and has no known exposure to drug-resistant cases 2

Pyridoxine (vitamin B6) 25-50 mg daily must be added for patients at risk of neuropathy: pregnant women, breastfeeding infants, HIV-infected patients, those with diabetes, alcoholism, malnutrition, chronic renal failure, or advanced age 1

---

Drug-Resistant TB (MDR-TB)

For multidrug-resistant tuberculosis, use at least 5 drugs in the intensive phase, including bedaquiline and a later-generation fluoroquinolone as core agents, with an intensive phase duration of 5-7 months after culture conversion. 1

Core Drug Selection (Strong Recommendations)

The following drugs should be included:

• Later-generation fluoroquinolone (levofloxacin or moxifloxacin) - mandatory inclusion 1
• Bedaquiline - mandatory inclusion 1

Additional Agents (Conditional Recommendations)

Build the regimen to achieve 5 drugs total by adding:

• Linezolid 1
• Clofazimine 1
• Cycloserine 1
• Pyrazinamide - only if susceptibility confirmed 1
• Ethambutol - only when other more effective drugs cannot be assembled 1

Injectable Agents (When Needed)

• Amikacin or streptomycin - only when susceptibility confirmed 1
• Carbapenem (with amoxicillin-clavulanic acid) 1
• Avoid kanamycin or capreomycin 1

Duration Parameters

• Intensive phase: 5-7 months after culture conversion 1
• Continuation phase: Use at least 4 drugs 1
• Total treatment duration: 15-21 months after culture conversion 1
• For pre-XDR-TB and XDR-TB: 15-24 months after culture conversion 1

Critical Pitfalls

Do not use the WHO standardized 9-12 month shorter regimen that includes kanamycin and drugs with documented resistance, as the guideline panel cannot recommend this approach compared to individualized all-oral regimens 1

---

Isoniazid-Resistant TB

Add a later-generation fluoroquinolone to a 6-month regimen of daily rifampin, ethambutol, and pyrazinamide for isoniazid-resistant tuberculosis 1

• Pyrazinamide duration: Can be shortened to 2 months in selected situations (noncavitary, lower burden disease, or pyrazinamide toxicity) 1
• Alternative approach: If pyrazinamide cannot be used, extend rifampin and ethambutol to minimum 12 months 2

---

Special Populations

HIV Co-infection

• Same drug regimen as HIV-negative patients 2
• Critical monitoring: Assess clinical and bacteriologic response closely; prolong therapy if slow or suboptimal response 2
• Avoid twice-weekly regimens in HIV-infected patients 1

Pregnancy

• All standard drugs safe: Rifampin, isoniazid, ethambutol, and pyrazinamide can be used 3
• Avoid streptomycin: Due to fetal ototoxicity 3
• Mandatory pyridoxine: 10 mg/day prophylactically 3

Renal Failure

• Dose adjustments required for streptomycin, ethambutol, and isoniazid based on creatinine clearance 3
• Ethambutol timing: Give 8 hours before hemodialysis in acute renal failure 3

Children

• Same principles as adults with appropriately adjusted doses 2
• Streptomycin substitution: Use instead of ethambutol in children too young to monitor for visual acuity 1, 2

---

Treatment Delivery

Directly observed therapy (DOT) should be used for all patients to ensure adherence and prevent drug resistance 1, 2

• Frequency flexibility: When using DOT, drugs may be given 5 days/week with adjusted total doses 1
• Case management interventions: Include patient education, field visits, reminders, incentives, and care coordination 1